0038 GMT - Cochlear looks fairly valued to Macquarie analysts following the share-price slump that followed the hearing-implant maker's first-half result. The analysts tell clients in a note that while December-half group unit sales and services revenue fell short of market expectations, there were still things to like about the Australia-listed company's latest update. Developed-market unit sales were up 6% on year on demand from adults and seniors, while group unit sales are still expected to grow by 10% going forward. EBIT was slightly higher than the Macquarie analysts had anticipated thanks to lower costs. Target price falls 2.4% to A$282.15 but Macquarie stays neutral on the stock, which is up 2.8% at A$270.11. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 16, 2025 19:38 ET (00:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.